5-Aminosalicylic acid inhibits colitis-associated but not sporadic colorectal neoplasia in a novel conditional Apc mouse model

Carcinogenesis

Volumn 30, Issue 7, 2009, Pages 1217-1224

  Koelink, Pim J ^a   Robanus Maandag, Els C ^a   Devilee, Peter ^a   Hommes, Daniel W ^a   Lamers, Cornelis B H W ^a   Verspaget, Hein W ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CASPASE 3; ENEMA; MESALAZINE; PLACEBO; SALAFOLK; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT DURATION; TUMOR VOLUME; WEIGHT REDUCTION;

AMINOSALICYLIC ACIDS; ANIMALS; ANTICARCINOGENIC AGENTS; CELL PROLIFERATION; COLITIS; COLORECTAL NEOPLASMS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; GENES, APC; MALE; MICE;

EID: 67650109585     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp113     Document Type: Article

References (28)

1. Greten,F.R. et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285-296.
2. Vagefi,P.A. et al. (2005) Colorectal cancer in patients with inflammatory bowel disease. Clin. Colorectal Cancer, 4, 313-319.
3. van Hogezand,R.A. et al. (2002) Malignancies in inflammatory bowel disease: Fact or fiction? Scand. J. Gastroenterol. Suppl., 236 48-53.
4. Velayos,F.S. et al. (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: A systematic review and metaanalysis of observational studies. Am. J. Gastroenterol., 100, 1345-1353.
5. Moser,A.R. et al. (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science, 247, 322-324.
6. Reya,T. et al. (2005) Wnt signalling in stem cells and cancer. Nature, 434, 843-850.
7. MacGregor,D.J. et al. (2000) Chemoprevention of colon cancer carcinogenesis by balsalazide: Inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouse. Int. J. Oncol., 17, 173-179.
8. Ritland,S.R. et al. (1999) Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: Lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. Clin. Cancer Res., 5 855-863.
9. Cooper,H.S. et al. (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab. Invest., 69 238-249.
10. Ni,J. et al. (1996) Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut, 39 234-241.
11. Cooper,H.S. et al. (2001) The role of mutant Apc in the development of dysplasia and cancer in the mouse model of dextran sulfate sodium-induced colitis. Gastroenterology, 121, 1407-1416.
12. Tanaka,T. et al. (2006) Dextran sodium sulfate strongly promotes colorectal carcinogenesis in Apc(Min/+) mice: Inflammatory stimuli by dextran sodium sulfate results in development of multiple colonic neoplasms. Int. J. Cancer, 118, 25-34.
13. Wong,M.H. et al. (2000) Genetic mosaic analysis based on Cre recombinase and navigated laser capture microdissection. Proc. Natl Acad. Sci. USA., 97, 12601-12606.
14. Kruidenier,L. et al. (2003) Attenuated mild colonic inflammation and improved survival from severe DSS-colitis of transgenic Cu/Zn-SOD mice. Free Radic. Biol. Med., 34, 753-765.
15. Allgayer,H. et al. (1989) Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology 97, 38-41.
16. Ireland,A. et al. (1990) Acetylation of 5-aminosalicylic acid by isolated human colonic epithelial cells. Clin. Sci. (Lond.), 78 105-111.
17. Palsmeier,R.K. et al. (1992) Investigation of the degradation mechanism of 5-aminosalicylic acid in aqueous solution. Pharm. Res. 9, 933-938.
18. Axelsson,L.G. et al. (1998) Experimental colitis induced by dextran sulphate sodium in mice: Beneficial effects of sulphasalazine and olsalazine. Aliment. Pharmacol. Ther., 12, 925-934.
19. Brown,W.A. et al. (2000) 5-aminosalicyclic acid and olsalazine inhibit tumor growth in a rodent model of colorectal cancer. Dig. Dis. Sci., 45, 1578-1584.
20. Clapper,M.L. et al. (2008) 5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of azoxymethane/dextran sulfate sodium-induced colitis. Inflamm. Bowel Dis., 14, 1341-1347.
21. Ikeda,I. et al. (2007) 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. Clin. Cancer Res., 13, 6527-6531.
22. Frieri,G. et al. (1999) Rectal and colonic mesalazine concentration in ulcerative colitis: Oral vs. oral plus topical treatment. Aliment. Pharmacol. Ther., 13, 1413-1417.
23. van Bodegraven,A.A. et al. (1996) Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment. Pharmacol. Ther., 10, 327-332.
24. Bus,P.J. et al. (1999) Mesalazine-induced apoptosis of colorectal cancer: On the verge of a new chemopreventive era? Aliment. Pharmacol. Ther., 13, 1397-1402.
25. Reinacher-Schick,A. et al. (2003) Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis, 24, 443-451.
26. Schwab,M. et al. (2008) PPAR{gamma} is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis, 29, 1407-1414.
27. Stolfi,C. et al. (2008) Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem. Pharmacol., 75, 668-676.
28. Schmiegel,W. et al. (2004) Effect of 5-Aminosalicylate (5-ASA) on the Recurrence Rate of Sporadic Colorectal Adenomas. Gastroenterology 126 (suppl. 2), A452.